Search

Your search keyword '"Abud-Mendoza, C."' showing total 285 results
Start Over Author "Abud-Mendoza, C."
285 results on '"Abud-Mendoza, C."'

1. POS0114 LUPUS NEPHRITIS AND RESPONSE TO TREATMENT IN LATIN AMERICA

Author

Quintana, R., primary, Nieto, R., additional, Fernández Ávila, D. C., additional, Serrano, R., additional, Harvey, G., additional, Hernández, L., additional, Roberts, K., additional, Scolnik, M., additional, Funes Soaje, C., additional, Alba, P., additional, Saurit, V., additional, García, M. A., additional, Berbotto, G., additional, Bellomio, V., additional, Patiño Grageda, W., additional, Gómez, G., additional, Pisoni, C., additional, Malvar, A., additional, Juarez, V., additional, Da Silva, N. A., additional, Monticielo, O. A., additional, Mariz, H. A., additional, Machado Ribeiro, F., additional, Borba, E. F., additional, Parente, L., additional, Torres, E., additional, Neira, O., additional, Massardo, L., additional, Aroca Martínez, G., additional, Cañas Davila, C. A., additional, Quintana López, G., additional, Toro-Gutierrez, C. E., additional, Moreno Alvarez, M., additional, Zúñiga, A., additional, Saavedra Salinas, M. A., additional, Portela Hernandez, M., additional, Fragoso Loyo, H., additional, Silveira, L., additional, García De La Torre, I., additional, Abud Mendoza, C., additional, Fonseca Hernández, M., additional, Esquivel-Valerio, J. A., additional, Acosta Colmán, I., additional, Losanto, J., additional, Mora Trujillo, C., additional, Zuñiga Corrales, K., additional, Muñoz Louis, R., additional, Rebella, M., additional, Danza, Á., additional, Ugarte-Gil, M. F., additional, Alarcón, G. S., additional, Sbarigia, U., additional, Zazzetti, F., additional, Orillion, A., additional, Pons-Estel, G., additional, and Pons-Estel, B., additional

Published
2024
Full Text
View/download PDF

2. POS1016 THE IMPACT OF ACTIVE LUPUS NEPHRITIS ON WORK PRODUCTIVITY IN PATIENTS FROM A LATIN AMERICAN LUPUS COHORT

Author

Pons-Estel, G., primary, Nieto, R., additional, Quintana, R., additional, Fernández Ávila, D. C., additional, Serrano, R., additional, Harvey, G., additional, Hernández, L., additional, Roberts, K., additional, Catoggio, L., additional, Subils, G., additional, Gobbi, C., additional, Bordon, F., additional, Ibañez Peña, P. D., additional, Berbotto, L. A., additional, Bertolaccini, M. C., additional, Rinesi, D. O., additional, De Los Ángeles Gargiulo, M., additional, Pisoni, C., additional, Serventi, J. M., additional, Buschiazzo, E., additional, Barbosa, V., additional, Monticielo, O. A., additional, Albanez de A. Da C. Andrade, C., additional, Machado Ribeiro, F., additional, Bonfa, E., additional, Borba, E. F., additional, Sato, E. I., additional, Bondi, A. P., additional, Donoso, S., additional, Aroca Martínez, G., additional, Medina, H., additional, Echeverri, A., additional, Molina-Rios, S., additional, Rubio Rivera, M., additional, Lopez Martinez, R., additional, Moreno Alvarez, M., additional, Vera Lastra, O. L., additional, Pérez Cristóbal, M., additional, Núñez Álvarez, C., additional, Amezcua-Guerra, L. M., additional, García-Valladares, I., additional, Abud Mendoza, C., additional, Galarza-Delgado, D. A., additional, Vázquez, M., additional, Paats, A., additional, Cieza Calderón, J. N., additional, Quiros Alva, A. M., additional, Muñoz Louis, R., additional, Pizzarossa, C., additional, Carlomango, A., additional, Gamboa-Cardenas, R. V., additional, Alarcón, G. S., additional, Sbarigia, U., additional, Zazzetti, F., additional, Orillion, A., additional, and Pons-Estel, B., additional

Published
2024
Full Text
View/download PDF

4. AB0578 LATIN-AMERICAN SYSTEMIC LUPUS ERYTHEMATOSUS CLUSTERS

Author

Quintana, R., primary, Nieto, R., additional, Gómez-Puerta, J. A., additional, Harvey, G. B., additional, Scolnik, M., additional, Meras, N., additional, Otaduy, C., additional, Novatti, E., additional, Arturi, V., additional, Sattler, M. E., additional, Pons-Estel, G., additional, Gonzalez Lucero, L., additional, Patiño Grageda, W., additional, Perez, N., additional, Pisoni, C., additional, Montandon, A. C. D. O. E. S., additional, Monticielo, O., additional, Duarte, A., additional, Machado Ribeiro, F., additional, Figueiredo Neves Yuki, E., additional, Reis Neto, E., additional, Guerra Herrera, I., additional, Mimica, M., additional, Aroca Martínez, G., additional, Tobón, G. J., additional, Quintana Lopez, G., additional, Cadena Bonfanti, A., additional, Moreno Alvarez, M. J., additional, Saavedra, M. A., additional, Portela, M., additional, Fragoso Loyo, H., additional, Silveira Torre, L. H., additional, Garcia Valladares, J. I., additional, Abud-Mendoza, C., additional, Esquivel Valerio, J. A., additional, Martínez, M., additional, Duarte, M., additional, Mora, C., additional, Ugarte-Gil, M. F., additional, Zavala, E., additional, Muñoz Louis, R., additional, Robaina, R., additional, Juarez, V., additional, Silveira, G., additional, Borba, E., additional, Catoggio, L., additional, Alarcon, G. S., additional, Zazzetti, F., additional, Orillion, A., additional, Sbarigia, U., additional, and Pons-Estel, B., additional

Published
2023
Full Text
View/download PDF

5. AB0580 PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): DATA FROM A MULTIETHNIC, MULTINATIONAL LATIN AMERICAN COHORT

Author

Serrano Morales, R. M., primary, Nieto, R., additional, Quintana, R., additional, Alba, P., additional, Porta, S., additional, Hernández, L., additional, Berbotto, G., additional, Bellomio, V. I., additional, Da Silva, N., additional, Monticielo, O., additional, Cavalcanti, F., additional, Machado Ribeiro, F., additional, Borba, E., additional, Bonfa, E., additional, Massardo, L., additional, Aroca Martínez, G., additional, Cadena Bonfanti, A., additional, Quintana Lopez, G., additional, Moreno Alvarez, M. J., additional, Esquivel Valerio, J. A., additional, Acosta-Colman, I., additional, Paats, A., additional, Mora, C., additional, Scolnik, M., additional, Fernández Ávila, D., additional, Funes Soaje, C., additional, Saurit, V., additional, García, M., additional, Kerzberg, E., additional, Gomez, G., additional, Pisoni, C., additional, Reis Neto, E., additional, Guerra Herrera, I., additional, Neira, O., additional, Cañas, C., additional, Saavedra, M. A., additional, Portela, M., additional, Fragoso Loyo, H., additional, Silveira Torre, L. H., additional, Garcia-De La Torre, I., additional, Ugarte-Gil, M. F., additional, Calvo Quiroz, A., additional, Muñoz Louis, R., additional, Robaina, R., additional, Juarez, V., additional, Danza, A., additional, Toro Gutierrez, C. E., additional, Abud-Mendoza, C., additional, Malvar, A., additional, Alarcon, G. S., additional, Orillion, A., additional, Sbarigia, U., additional, Zazzetti, F., additional, Pons-Estel, G., additional, and Pons-Estel, B., additional

Published
2023
Full Text
View/download PDF

6. POS0712 YEAR-4 OBSERVATIONAL FOLLOW-UP OF BELIMUMAB SAFETY (MORTALITY AND MALIGNANCIES) IN PATIENTS WITH SLE WHO COMPLETED A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED SAFETY STUDY

Author

Sheikh, S., primary, Scheinberg, M., additional, Wei, J. C. C., additional, Tegzová, D., additional, Stohl, W., additional, Acayaba De Toledo, R., additional, Mucenic, T., additional, Abello Banfi, M. R., additional, Maksimowicz-Mckinnon, K., additional, Abud-Mendoza, C., additional, Navarra, S., additional, García, M., additional, Garcia-De La Torre, I., additional, Liu, A., additional, Roy, A., additional, Wilde, P., additional, Fernandes, S., additional, Harris, J., additional, and Roth, D., additional

Published
2022
Full Text
View/download PDF

8. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

Author

Brunner, Hermine, Ruperto, N., Tzaribachev, N., Horneff, G., Wouters, C., Panaviene, V., Chasnyk, V., Abud-Mendoza, C., Cuttica, R., Reiff, A., Maldonado-Velázquez, M., Rubio-Perez, N., Alexeeva, Ekaterina, Joos, R., Keltsev, V., Nasonov, E., Kingsbury, D., Bandeira, M., Silverman, E., Weller-Heinemann, F., van Royen-Kerkhof, A., Mendelsohn, Alan, Kim, Lilianne, Lovell, D., and Martini, A.

Published
2014
Full Text
View/download PDF

10. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Author

Brunner, HI, Abud-Mendoza, C, Viola, DO, Penades, IC, Levy, D, Anton, J, Calderon, JE, Chasnyk, VG, Ferrandiz, MA, Keltsev, V, Gastanaga, MEP, Shishov, M, Boteanu, AL, Henrickson, M, Bass, D, Clark, K, Hammer, A, Ji, BN, Nino, A, Roth, DA, Struemper, H, Wang, ML, Martini, A, Lovell, D, Ruperto, N, Paediat Rheumatology, and Pediat Rheumatology Collab

Subjects
systemic lupus erythematosus, treatment, DMARDs (biologic)
Abstract

Objectives This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE). Methods Patients (5 to 17 years) were randomised to belimumab 10 mg/kg intravenous or placebo every 4 weeks, plus standard SLE therapy. Primary endpoint: SLE Responder Index (SRI4) response rate (Week 52). Key major secondary endpoints: proportion of patients achieving the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) response using 50 and '30 alternative' definitions (Week 52), and sustained response (Weeks 44 to 52) by SRI4 and Parent Global Assessment of well-being (Parent-global). Safety and pharmacokinetics were assessed. Study not powered for statistical testing. Results Ninety-three patients were randomised (belimumab, n=53; placebo, n=40). At Week 52, there were numerically more SRI4 responders with belimumab versus placebo (52.8% vs 43.6%; OR 1.49 (95% CI 0.64 to 3.46)). PRINTO/ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)). Serious adverse events were reported in 17.0% of belimumab patients and 35.0% of placebo patients; one death occurred (placebo). Week-52, geometric mean (95% CI) belimumab trough concentration was 56.2 (45.2 to 69.8) mu g/mL. Conclusion The belimumab intravenous pharmacokinetics and benefit-risk profile in cSLE are consistent with adult belimumab studies and the 10 mg/kg every 4 weeks dose is appropriate.

Published
2020

13. OP0291 TOFACITINIB FOR THE TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY

Author

Ruperto, N., primary, Synoverska, O., additional, Ting, T., additional, Abud-Mendoza, C., additional, Spindler, A., additional, Vyzhga, Y., additional, Marzan, K., additional, Keltsev, V., additional, Tirosh, I., additional, Imundo, L., additional, Jerath, R., additional, Kingsbury, D., additional, Sözeri, B., additional, Vora, S., additional, Prahalad, S., additional, Zholobova, E., additional, Butbul Aviel, Y., additional, Chasnyk, V., additional, Lerman, M., additional, Nanda, K., additional, Schmeling, H., additional, Tory, H., additional, Uziel, Y., additional, Viola, D. O., additional, Posner, H., additional, Kanik, K., additional, Wouters, A., additional, Chang, C., additional, Zhang, R., additional, Lazariciu, I., additional, Hsu, M. A., additional, Suehiro, R., additional, Martini, A., additional, Lovell, D. J., additional, and Brunner, H., additional

Published
2020
Full Text
View/download PDF

14. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabʼs Efficacy in MTX iNadequate rEsponders (SERENE))

Author

Emery, P, Deodhar, A, Rigby, W F, Isaacs, J D, Combe, B, Racewicz, A J, Latinis, K, Abud-Mendoza, C, Szczepański, L J, Roschmann, R A, Chen, A, Armstrong, G K, Douglass, W, and Tyrrell, H

Published
2010
Full Text
View/download PDF

20. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

Author

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio Pérez N, Silva CA, Abud Mendoza C, Burgos Vargas R, Gerloni V, Melo Gomes JA, Saad Magalhães C, Sztajnbok F, Goldenstein Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization, Pediatric Rheumatology Collaborative Study G.r.o.u.p. Collaborators Huemer C, Meunier BB, Deslandre CJ, Lemelle I, Mouy R, Prieur AM, Horneff G, Huppertz HI, Foeldvari I, Minden K, Ravelli A, Loy A, Cortis E, Falcini F, Nunez AF, Chavez J, Blanco FJ, Hofer M, Eberhard BA, Kivitz A, Punaro M, Olson N, Gardiner L., ALESSIO, MARIA, Ruperto, N, Lovell, Dj, Quartier, P, Paz, E, Rubio Pérez, N, Silva, Ca, Abud Mendoza, C, Burgos Vargas, R, Gerloni, V, Melo Gomes, Ja, Saad Magalhães, C, Sztajnbok, F, Goldenstein Schainberg, C, Scheinberg, M, Penades, Ic, Fischbach, M, Orozco, J, Hashkes, Pj, Hom, C, Jung, L, Lepore, L, Oliveira, S, Wallace, Ca, Sigal, Lh, Block, Aj, Covucci, A, Martini, A, Giannini, Eh, Paediatric Rheumatology INternational Trials, Organization, Collaborators Huemer C, Pediatric Rheumatology Collaborative Study G. r. o. u. p., Meunier, Bb, Deslandre, Cj, Lemelle, I, Mouy, R, Prieur, Am, Horneff, G, Huppertz, Hi, Foeldvari, I, Minden, K, Ravelli, A, Loy, A, Cortis, E, Falcini, F, Alessio, Maria, Nunez, Af, Chavez, J, Blanco, Fj, Hofer, M, Eberhard, Ba, Kivitz, A, Punaro, M, Olson, N, and Gardiner, L.

Subjects
Male, medicine.medical_specialty, Immunoconjugates, Adolescent, Arthritis, Placebo, Severity of Illness Index, law.invention, Abatacept, Juvenile Arthritis Disease Activity Score, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Humans, Range of Motion, Articular, Child, Infusions, Intravenous, Tumor Necrosis Factor-alpha, business.industry, General Medicine, medicine.disease, Arthritis, Juvenile, Rheumatology, Surgery, Treatment Outcome, Antirheumatic Agents, Female, business, Juvenile rheumatoid arthritis, medicine.drug
Abstract

Summary Background Some children with juvenile idiopathic arthritis either do not respond, or are intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour necrosis factor (TNF) drugs. We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments. Methods We did a double-blind, randomised controlled withdrawal trial between February, 2004, and June, 2006. We enrolled 190 patients aged 6–17 years, from 45 centres, who had a history of active juvenile idiopathic arthritis; at least five active joints; and an inadequate response to, or intolerance to, at least one disease-modifying antirheumatic drug. All 190 patients were given 10 mg/kg of abatacept intravenously in the open-label period of 4 months. Of the 170 patients who completed this lead-in course, 47 did not respond to the treatment according to predefined American College of Rheumatology (ACR) paediatric criteria and were excluded. Of the patients who did respond to abatacept, 60 were randomly assigned to receive 10 mg/kg of abatacept at 28-day intervals for 6 months, or until a flare of the arthritis, and 62 were randomly assigned to receive placebo at the same dose and timing. The primary endpoint was time to flare of arthritis. Flare was defined as worsening of 30% or more in at least three of six core variables, with at least 30% improvement in no more than one variable. We analysed all patients who were treated as per protocol. This trial is registered, number NCT00095173. Findings Flares of arthritis occurred in 33 of 62 (53%) patients who were given placebo and 12 of 60 (20%) abatacept patients during the double-blind treatment (p=0·0003). Median time to flare of arthritis was 6 months for patients given placebo (insufficient events to calculate IQR); insufficient events had occurred in the abatacept group for median time to flare to be assessed (p=0·0002). The risk of flare in patients who continued abatacept was less than a third of that for controls during that double-blind period (hazard ratio 0·31, 95% CI 0·16–0·95). During the double-blind period, the frequency of adverse events did not differ in the two treatment groups. Adverse events were recorded in 37 abatacept recipients (62%) and 34 (55%) placebo recipients (p=0·47); only two serious adverse events were reported, both in controls (p=0·50). Interpretation Selective modulation of T-cell costimulation with abatacept is a rational alternative treatment for children with juvenile idiopathic arthritis. Funding Bristol-Myers Squibb.

Published
2008
Full Text
View/download PDF

21. AB1137 Inflammatory and erosive arthritis, a common unknown manifestation of vogt-koyanagi-harada disease (VKHD)

Author

Ramos-Bello, D., primary, Pedro-Martínez, A.J., additional, Aguilera Barragán-Pickens, G., additional, Acevedo-Castañeda, E.S., additional, López-Ferretis, H., additional, Martínez-Flores, G., additional, Luna-Zúñiga, T.A., additional, Santillán-Guerrero, E., additional, Moreno-Valdés, R., additional, Saldaña-Baarnard, M., additional, Cuevas-Orta, E., additional, and Abud-Mendoza, C., additional

Published
2018
Full Text
View/download PDF

22. SAT0216 The addition of colchicine to metotrexate might help achieve low disease activity in patients with early rheumatoid arthritis by downregulating the activity of caspase-1.

Author

Ramos-Bello, D., primary, Pedro-Martínez, A. J., additional, Aguilera Barragán-Pickens, G., additional, Acevedo-Castañeda, E. S., additional, López-Ferretis, H., additional, Martínez-Flores, G., additional, Luna-Zúñiga, T. A., additional, Santillán-Guerrero, E., additional, Moreno-Valdés, R., additional, Saldaña-Baard, M., additional, Cuevas-Orta, E., additional, Álvares-Quiroga, C., additional, González-Amaro, R., additional, and Abud-Mendoza, C., additional

Published
2018
Full Text
View/download PDF

25. SAT0220 Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a phase 3b/4 randomised trial

Author

Calabrese, L. H., primary, Abud-Mendoza, C., additional, Lindsey, S., additional, Lee, S.-H., additional, Takiya, L., additional, Iikuni, N., additional, Soma, K., additional, Luo, Z., additional, and Fleischmann, R., additional

Published
2018
Full Text
View/download PDF

28. FRI0264 Epidemiologic profile of erectile dysfunction in sle: a multi-center study in latin american patients

Author

Merayo-Chalico, J, primary, Barrera-Vargas, A, additional, Morales-Padilla, S, additional, Garza, R Reyna-De la, additional, Vázquez-Rodríguez, R, additional, Sotomayor, M, additional, Gόmez-Martín, D, additional, Alcocer-Varela, J, additional, Abud-Mendoza, C, additional, Martínez-Martínez, M, additional, Colunga-Pedraza, I, additional, Uriarte-Hernández, C, additional, Acosta-Hernández, I, additional, Fajardo, D, additional, García-García, C, additional, and Padilla-Ortíz, D, additional

Published
2017
Full Text
View/download PDF

34. Multizentrische, doppelblinde, randomisierte Studie von Golimumab bei pädiatrischen Patienten mit aktiver pJIA trotz Methotrexat: Ergebnisse nach 48 Wochen

Author

Brunner, H, Horneff, G, Ruperto, N, Tzaribachev, N, Wouters, C, Chasnyk, V, Cuttica, R, Keltsev, V, Nasonov, E, Kingsbury, D, Weller-Heinemann, F, Lovell, DJ, Martini, A, Panaviene, VV, Abud Mendoza, C, Reiff, A, Alexeeva, E, Joos, R, Bandeira, M, Silverman, E, van Royen-Kerkhof, A, Kim, L, Rubio-Perez, N, Brunner, H, Horneff, G, Ruperto, N, Tzaribachev, N, Wouters, C, Chasnyk, V, Cuttica, R, Keltsev, V, Nasonov, E, Kingsbury, D, Weller-Heinemann, F, Lovell, DJ, Martini, A, Panaviene, VV, Abud Mendoza, C, Reiff, A, Alexeeva, E, Joos, R, Bandeira, M, Silverman, E, van Royen-Kerkhof, A, Kim, L, and Rubio-Perez, N

Published
2016

35. Urinary sediment suggests lupus nephritis histology

Author

Martínez-Martínez, M U, primary, Llamazares-Azuara, L M de G, additional, Martínez-Galla, D, additional, Mandeville, P B, additional, Valadez-Castillo, F, additional, Román-Acosta, S, additional, Borjas-García, J A, additional, and Abud-Mendoza, C, additional

Published
2016
Full Text
View/download PDF

39. Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus.

Author

Cruz‐González, D. de J., Gómez‐Martin, D., Layseca‐Espinosa, E., Baranda, L., Abud‐Mendoza, C., Alcocer‐Varela, J., González‐Amaro, R., and Monsiváis‐Urenda, A. E.

Subjects
SYSTEMIC lupus erythematosus, KILLER cells, IMMUNOREGULATION, CD3 antigen, IMMUNOGLOBULINS, PATIENTS
Abstract

Summary: Natural killer (NK) cells participate in the regulation of the immune response. However, the immunomodulatory function of NK cells in systemic lupus erythematosus (SLE) is not well understood. The aim of this study was to evaluate the regulatory function of NK cells in SLE patients and to identify the NK cells involved in the pathogenesis of this complex disease. We analysed the expression of NK receptors and co‐stimulatory molecules in peripheral NK cells (CD3–CD56+) from SLE patients, as well as the numbers of human leucocyte antigen D‐related (HLA‐DR)/CD11c+ NK cells. In addition, NK cell regulatory function was assessed by the detection of NK cell‐mediated dendritic cell (DC) lysis. We found that SLE patients showed increased numbers of immunoglobulin‐like transcript 2 (ILT2)+, CD86+ and CD134+ NK cells. Furthermore, NK cells from SLE patients induced higher levels of DC lysis. We were able to identify a new subset of NK cells co‐expressing CD11c and HLA‐DR. These atypical NK cells were increased in SLE patients when compared with controls. We have identified an expanded new subset of NK cells in SLE patients. This is the first study, to our knowledge, which demonstrates that NK cells in SLE patients have an altered phenotype with a high expression of receptors characteristic of dendritic cells. Our results suggest that the impairment in the regulatory function of NK cells, together with the increased number of DC‐like NK cells, could play an important role in the development of SLE and highlight the importance of NK cells as a future therapeutic target. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

45. Evaluación del estado nutricio en una población mexicana de pacientes adultos con artritis reumatoide

Author

Puente Torres,L., Hurtado Torres,G. F., Abud Mendoza,C., and Bravo Ramírez,A.

Subjects
Evaluación nutricia, Estado nutricia, Artritis reumatoide
Abstract

Antecedentes: La artritis reumatoide (AR) representa un estado inflamatorio crónico que se acompaña de potenciales complicaciones a nivel multiorgánico. Se ha descrito una alta prevalencia de alteraciones nutricias en pacientes con AR, las cuales en conjunto, pueden repercutir negativamente en el curso y pronóstico de la enfermedad ya sea a través de un incremento en la incidencia de morbilidades cardiovasculares o bien imponiendo limitaciones funcionales adicionales a las ya existentes por la enfermedad de base.Propósito: Evaluar nutricionalmente en términos de composición corporal y patrón de ingesta dietaria a una población mexicana con diagnóstico de AR.Material y métodos: Se evaluaron 100 pacientes ambulatorios con el diagnóstico de AR que acuden al servicio de consulta externa de un centro regional de reumatología en San Luís Potosí México. Se determinaron las variables antropométricas, composición corporal por análisis de bioimpedancia eléctrica (BIA) y patrones dietarios.Resultados: Se incluyeron un total de 87 (87%) mujeres y 13 (13%) varones. La edad media fue de 47,6 ± 13,3 años, con una evolución promedio de la enfermedad de 10,18 ± 9,02 años. 79% de los pacientes se encontraban en clase funcional II y 21% en clase funcional III. El índice de masa corporal promedio fue de 26,8 ± 4,4 kg/m2 , 65% de los pacientes presentaron índices de masa corporal (IMC) en rango de sobrepeso u obesidad y solo el 2% en rango de desnutrición. 48% de la muestra presentó depleción de masa magra y 94% presentaron incremento en el porcentaje de grasa corporal estimados por BIA y antropometría. 34 pacientes (34%) presentaron circunferencia abdominal por arriba de los puntos de corte para el diagnóstico de síndrome metabólico. En cuanto a las características cualitativas de la dieta el 90% de la muestra consumía una dieta inadecuada, con una ingesta calórica diaria promedio de 26.49 ± 8.24 kcal. por día; la ingesta de proteínas fue óptima en la totalidad de la población. Conclusión: Existe una elevada prevalencia de alteraciones nutricias en la población mexicana con AR, los hallazgos mas frecuentes en este estudio fueron disminución en masa magra, incremento en reserva grasa, ingesta calórica disminuida y dietas cualitativamente inadecuadas. Se requieren estrategias de intervención para el abordaje y tratamiento nutricional de pacientes con AR como medidas potenciales que modifiquen el curso y pronóstico de la enfermedad.

Published
2009

46. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

Author

Ruperto, N, Lovell, Dj, Quartier, P, Paz, E, RUBIO PÉREZ, N, Silva, Ca, ABUD MENDOZA, C, BURGOS VARGAS, R, Gerloni, V, MELO GOMES JA, SAAD MAGALHÃES, C, Sztajnbok, F, GOLDENSTEIN SCHAINBERG, C, Scheinberg, M, Penades, Ic, Fischbach, M, Orozco, J, Hashkes, Pj, Hom, C, Jung, L, Lepore, L, Oliveira, S, Wallace, Ca, Sigal, Lh, Block, Aj, Covucci, A, Martini, Alberto, Giannini, Eh, PEDIATRIC RHEUMATOLOGY COLLABORATIVE STUDY, and Group

Published
2008

47. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Author

Smolen, Js, Beaulieu, A, Rubbert Roth, A, Ramos Remus, C, Rovensky, J, Alecock, E, Woodworth, T, Alten, R, Tate, G, Maldonado Cocco JA, Scali, J, Taylor, A, Hanrahan, P, Nash, P, Smith, M, Smolen, J, Koeller, M, Eberl, G, Dunky, A, Zamani, O, Simon, Jc, Scheinberg, Ma, Yaneva, D, Oparanov, B, Karastatev, D, Atkins, C, Bell, M, Haraoui, B, Marin, L, Thorne, Jc, Zummer, M, Khraishi, M, Mckendry, Rj, Pandith, V, Mccarthy, T, Lau, Cs, Li, E, Mok, Cc, Kahan, A, Wendling, D, Bardin, T, Nguyen, M, Claudepierre, P, Berenbaum, F, Puechal, X, Fiehn, C, Heilig, B, Hellmich, B, Lange, U, Lorenz, Hm, Wendler, J, Czirijak, L, Hodinka, L, Szekanecz, Z, Molad, Y, Nahir, M, Rosner, I, Rubinow, A, Abu Shakra, M, Elkayam, O, Marcolongo, R, Bagnato, G, Triolo, G, Trotta, F, DE VITA, Salvatore, Lugo, Ge, Abud Mendoza, C, Pineca, C, de la Torre IG, Pacheco, C, Leong, Kh, Koh, Dr, Dudler, J, Villiger, P, Lothrenoo, W, Asavatanabodee, P, Nilganuwong, S, and Totemchokchaiyakarn, K.

Subjects
rheumatoid arthritis, interleukin-6
Published
2008

48. [Assessment of nutritional status in a Mexican population of adult patients with rheumatoid arthritis]

Author

Puente Torres L, GILBERTO FABIAN HURTADO-TORRES, Abud Mendoza C, and Bravo Ramírez A

Subjects
Arthritis, Rheumatoid, Male, Nutritional status, Evaluación nutricia, Humans, Nutritional Status, Female, Estado nutricia, Artritis reumatoide, Rheumatoid arthritis, Middle Aged, Nutritional assessment, Mexico
Abstract

Antecedentes: La artritis reumatoide (AR) representa un estado inflamatorio crónico que se acompaña de potenciales complicaciones a nivel multiorgánico. Se ha descrito una alta prevalencia de alteraciones nutricias en pacientes con AR, las cuales en conjunto, pueden repercutir negativamente en el curso y pronóstico de la enfermedad ya sea a través de un incremento en la incidencia de morbilidades cardiovasculares o bien imponiendo limitaciones funcionales adicionales a las ya existentes por la enfermedad de base.Propósito: Evaluar nutricionalmente en términos de composición corporal y patrón de ingesta dietaria a una población mexicana con diagnóstico de AR.Material y métodos: Se evaluaron 100 pacientes ambulatorios con el diagnóstico de AR que acuden al servicio de consulta externa de un centro regional de reumatología en San Luís Potosí México. Se determinaron las variables antropométricas, composición corporal por análisis de bioimpedancia eléctrica (BIA) y patrones dietarios.Resultados: Se incluyeron un total de 87 (87%) mujeres y 13 (13%) varones. La edad media fue de 47,6 ± 13,3 años, con una evolución promedio de la enfermedad de 10,18 ± 9,02 años. 79% de los pacientes se encontraban en clase funcional II y 21% en clase funcional III. El índice de masa corporal promedio fue de 26,8 ± 4,4 kg/m2 , 65% de los pacientes presentaron índices de masa corporal (IMC) en rango de sobrepeso u obesidad y solo el 2% en rango de desnutrición. 48% de la muestra presentó depleción de masa magra y 94% presentaron incremento en el porcentaje de grasa corporal estimados por BIA y antropometría. 34 pacientes (34%) presentaron circunferencia abdominal por arriba de los puntos de corte para el diagnóstico de síndrome metabólico. En cuanto a las características cualitativas de la dieta el 90% de la muestra consumía una dieta inadecuada, con una ingesta calórica diaria promedio de 26.49 ± 8.24 kcal. por día; la ingesta de proteínas fue óptima en la totalidad de la población. Conclusión: Existe una elevada prevalencia de alteraciones nutricias en la población mexicana con AR, los hallazgos mas frecuentes en este estudio fueron disminución en masa magra, incremento en reserva grasa, ingesta calórica disminuida y dietas cualitativamente inadecuadas. Se requieren estrategias de intervención para el abordaje y tratamiento nutricional de pacientes con AR como medidas potenciales que modifiquen el curso y pronóstico de la enfermedad. Background: Rheumatoid arthritis (RA) represents a life-long chronic inflammatory process frequently associated to potential multiorganic complications. Cardiovascular diseases and nutritional alterations are increased in AR populations and represent potential factors that alter negatively the disease course and prognosis. Purpose: To evaluate nutritional status from a Mexican AR population, including body composition, anthropometrics and dietary patterns. Material and methods: There were included 100 RA outpatients from a regional rheumatic centre located in San Luis Potosi México. Nutritional assessment included anthropometric evaluation, bioelectrical impedance analysis (BIA) and dietary patterns evaluation. Results: 100 RA out-patients were included. Mean age was 47.6 ± 13.3 years, with a mean disease course of 10.18 ± 9.02. 79% of patients were in RA functional class II and 21% in class III. Average body mass index 26.8 ± 4.4 kg/m2 According to body mass index categories, 65% patients were within the range of overweight and obesity and 2% of patients were undernourished. Mean waist circumference 86.7 ± 11.1 cm, 34% of patients showed waist circumference values over the limits established for the definition of metabolic syndrome. Lean body mass was diminished in 48% patients. Body fat mass estimated by anthropometry and BIA was increased in 94 patients (94%). Dietary parameters: Mean energy intake was 26.4 ± 8.2 kcal/kg. There was qualitative nutritional inadequacy in 90 patients (90%). Protein intake was optimal in all the patients. Conclusion: Nutritional alterations are highly prevalent in Mexican RA population; our study showed freefat mass depletion, low caloric intake, dietary inadequate parameters and fat mass increments as the more prevalent findings. Nutritional assessment and nutritional strategies are recommended as potential measures to improve RA clinical course and prognosis.

Published
2007

49. Urinary sediment suggests lupus nephritis histology.

Author

Martínez-Martínez, M. U., de G. Llamazares-Azuara, L. M., Martínez-Galla, D., Mandeville, P. B., Valadez-Castillo, F., Román-Acosta, S., Borjas-García, J. A., and Abud-Mendoza, C.

Subjects
URINALYSIS, RENAL biopsy, LUPUS nephritis, LEUCOCYTES, ERYTHROCYTES
Abstract

Objectives: The objective of this paper was to evaluate correlations between kidney biopsy indexes (activity and chronicity) and urinary sediment findings; the secondary objective was to find which components of urinary sediment can discriminate proliferative from other classes of lupus nephritis. Methods: Lupus nephritis patients scheduled for a kidney biopsy were included in our study. The morning before the kidney biopsy, we took urine samples from each patient. Receiver operating characteristic (ROC) curves were plotted to determine the area under the curve (AUC) of each test for detecting proliferative lupus nephritis; a classification tree was calculated to select a set of values that best-predicted lupus nephritis classes. Results: We included 51 patients, 36 of whom were women (70.6%). Correlations of lupus nephritis activity index with the counts in the urinary sediment of erythrocytes (isomorphic and dysmorphic), acanthocytes, and leukocytes were 0.65 (p<0.0001) 0.62 (p<0.0001) and 0.22 (p=0.1228), respectively. Correlations of lupus nephritis chronicity index with the counts of erythrocytes, acanthocytes, and leukocytes were 0.60 (p≤0.0001), 0.52 (p=0.0001) and 0.17 (p=0.2300), respectively. Our classification tree had an accuracy of 84.3%. Conclusions: Evaluation of urine sediment reflects lupus nephritis histology. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results